ConductScience.org, home

Paper32010993

Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.

Sidana S and 17 others. Am J Hematol, 2020. Cited by 41 papers, by iCite.

Cite this record

ConductScience Library. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. Papers, record 32010993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32010993

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
PubMed
Journal
Am J Hematol
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
2.45
iCite
Revised in PubMed
2023-09-19
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sidana SSurbhihttps://orcid.org/0000-0003-3288-7614
2Muchtar EEli
3Sidiqi MHM Hasibhttps://orcid.org/0000-0003-1089-3853
4Jevremovic DDragan
5Dispenzieri AAngelahttps://orcid.org/0000-0001-8780-9512
6Gonsalves WWilsonhttps://orcid.org/0000-0001-6890-969X
7Buadi FFrancis
8Lacy MQMartha Q
9Hayman SRSuzanne R
10Kourelis TTaxiarchishttps://orcid.org/0000-0001-8573-9434
11Kapoor PPrashant
12Go RSRonald S
13Warsame RRahmahttps://orcid.org/0000-0003-0240-0326
14Leung NNelsonhttps://orcid.org/0000-0002-5651-1411
15Rajkumar SVS Vincenthttps://orcid.org/0000-0002-5862-1833
16Kyle RARobert A
17Gertz MAMorie Ahttps://orcid.org/0000-0002-3853-5196
18Kumar SKShaji K

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Flow CytometryMajor topic
Immunoglobulin Light-chain AmyloidosisMajor topic
Neoplasm, ResidualMajor topic
Aged
Female
Humans
Male
Middle Aged
Treatment Outcome

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P50 CA186781NCI NIH HHSUnited StatesP50CA186781PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128919633Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.Leukemia2018https://conductscience.org/library/papers/28919633PubMed
229142197Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.Sci Rep2017https://conductscience.org/library/papers/29142197PubMed
325619868Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.Cytometry B Clin Cytom2016https://conductscience.org/library/papers/25619868PubMed
425115890A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.Blood2014https://conductscience.org/library/papers/25115890PubMed
523624626Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.Am J Physiol Heart Circ Physiol2013https://conductscience.org/library/papers/23624626PubMed
627511158International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol2016https://conductscience.org/library/papers/27511158PubMed
729568089The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response.Leukemia2018https://conductscience.org/library/papers/29568089PubMed
816794250Dangerous small B-cell clones.Blood2006https://conductscience.org/library/papers/16794250PubMed
930249784Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.Blood2018https://conductscience.org/library/papers/30249784PubMed
1029795385Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.Blood Cancer J2018https://conductscience.org/library/papers/29795385PubMed
1123733781Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.J Clin Oncol2013https://conductscience.org/library/papers/23733781PubMed
1227118453Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.Blood2016https://conductscience.org/library/papers/27118453PubMed
1323091105New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.J Clin Oncol2012https://conductscience.org/library/papers/23091105PubMed
1427729322The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.Blood2017https://conductscience.org/library/papers/27729322PubMed
1531544536Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.Amyloid2020https://conductscience.org/library/papers/31544536PubMed
1628287637Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?Bone Marrow Transplant2017https://conductscience.org/library/papers/28287637PubMed
1727632282Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.JAMA Oncol2017https://conductscience.org/library/papers/27632282PubMed
1828550043AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.Blood2017https://conductscience.org/library/papers/28550043PubMed
1928104919Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Leukemia2017https://conductscience.org/library/papers/28104919PubMed
2029964192Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis.Biol Blood Marrow Transplant2018https://conductscience.org/library/papers/29964192PubMed

See all 23 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
41462937Proving Bone Marrow Plasma Cell Clonality by Flow Cytometry: An Important Tool in the Diagnosis of Immunoglobulin Light-Chain Amyloidosis.Biomedicines2025https://conductscience.org/library/papers/41462937PubMed
39587494Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.BMC Cancer2024https://conductscience.org/library/papers/39587494PubMed
39485557Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response.Clin Exp Med2024https://conductscience.org/library/papers/39485557PubMed
39384609Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.Blood Cancer J2024https://conductscience.org/library/papers/39384609PubMed
39179452Autologous stem cell transplantation in AL amyloidosis: Muddy waters.Blood Rev2024https://conductscience.org/library/papers/39179452PubMed
39157610HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.EJHaem2024https://conductscience.org/library/papers/39157610PubMed
39139790A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots.Front Med (Lausanne)2024https://conductscience.org/library/papers/39139790PubMed
38619663Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.J Cancer Res Clin Oncol2024https://conductscience.org/library/papers/38619663PubMed
36620914Bad players in AL amyloidosis in the current era of treatment.Expert Rev Hematol2023https://conductscience.org/library/papers/36620914PubMed
36215675Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.J Clin Oncol2023https://conductscience.org/library/papers/36215675PubMed
34681575Biomarkers in AL Amyloidosis.Int J Mol Sci2021https://conductscience.org/library/papers/34681575PubMed
34006856Comprehensive Review of AL amyloidosis: some practical recommendations.Blood Cancer J2021https://conductscience.org/library/papers/34006856PubMed
33966111Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.J Cancer Res Clin Oncol2022https://conductscience.org/library/papers/33966111PubMed
33594045Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood Cancer J2021https://conductscience.org/library/papers/33594045PubMed
33230879Characterization and prognostic implication of delayed complete response in AL amyloidosis.Eur J Haematol2021https://conductscience.org/library/papers/33230879PubMed
33099434Future Perspectives.Hematol Oncol Clin North Am2020https://conductscience.org/library/papers/33099434PubMed
32885146Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management.Hemasphere2020https://conductscience.org/library/papers/32885146PubMed
32754033Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses.Front Pharmacol2020https://conductscience.org/library/papers/32754033PubMed
32634163Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.PLoS One2020https://conductscience.org/library/papers/32634163PubMed
32531894CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.Int J Mol Sci2020https://conductscience.org/library/papers/32531894PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32010993

GET https://conductscience.org/api/papers/v1/32010993/references?page=2